Keyword: Chiesi Farmaceutici
The Celgene-partnered single-domain antibody specialist will use the cash to complete phase 1 trials of three oncology and rare disease drugs.
Kamada has hit another hurdle in its bid to bring the first inhaled treatment for AAT deficiency to market as an alternative to intravenous drugs.
The split gives uniQure full rights to AMT-060 but leaves it without a partner to cofund R&D as it closes in on the start of a pivotal trial.
The key to strengthening the lungs of premature babies may be held by spiders—namely, the way they spin their webs.
Charles River Laboratories has sealed the extension of a previous six-year early drug discovery contract in the field of respiratory disease with Chiesi Farmaceutici.
Aptuit, a CRO focused on early to mid-phase drug development, has inked a deal with Chiesi Farmaceutici to develop new drugs for idiopathic pulmonary fibrosis.
Chiesi Farmaceutici has bought Atopix Therapeutics for its pipeline of asthma treatments.
In its Series A announced today Glycomine, an early-stage biotech working on replacement therapies for rare diseases, raised $12 million with help from Sanderling Ventures and Chiesi Ventures.